Billionaire investor Stanley Druckenmiller has made headlines once again by allocating over a billion dollars to three lesser-known equities through his Duquesne Family Office. The latest filings from the Securities and Exchange Commission reveal Druckenmiller’s strategic bets on stocks in the technology and healthcare sectors.
As of the first quarter of 2025, Duquesne’s largest position is in Natera Inc. (NTRA), a tech company specializing in genetic testing for early detection of hereditary conditions like cancer. The filing shows that Duquesne now holds 3.402 million NTRA shares valued at approximately $521.48 million.
In addition to NTRA, the firm has also taken a significant stake in Teva Pharmaceutical Industries (TEVA), an Israeli company known for manufacturing generic medicines. Duquesne has acquired 14.879 million shares of TEVA, amounting to around $252.955 million.
Another major investment by Druckenmiller’s firm is in the South Korean e-commerce giant Coupang Inc. (CPNG). With over 9.3 million shares of CPNG valued at roughly $252.659 million, Duquesne Family Office has shown confidence in the growth potential of this company.
The combined value of Duquesne’s holdings in NTRA, TEVA, and CPNG now exceeds $1.02 billion, representing approximately 33% of the firm’s $3.06 billion portfolio. Apart from these three key positions, Druckenmiller’s top holdings as of Q1 2025 include Woodward Inc. (WWD) valued at $226.13 million, Philip Morris International (PM) at $193.67 million, and Coherent (COHR) at $175.27 million.
On the flip side, the firm has reduced its stake in companies like Seagate Technology (STX), Skechers USA (SKX), United Airlines (UAL), and SLM Corp (SLM) during the same period.
For more updates on investment strategies and market trends, follow us on X, Facebook, and Telegram. Don’t miss out on the latest updates by subscribing to our email alerts. Stay informed about price action and explore The Daily Hodl Mix for a comprehensive overview of the market.
(Image credit: Midjourney)